TickerFacts.

Interpace Biosciences, Inc. (IDXG): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2018-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$11.47M
As of 2025-12-31
$11.30M
As of 2026-06-30
-29.3%
3-year compound annual growth
-16.5%
5-year compound annual growth
$95.78M2010-12-31: $54.88M2011-12-31: $53.86M2012-12-31: $42.82M2013-12-31: $36.59M2014-12-31: $95.78M2015-12-31: $54.67M2016-12-31: $35.25M2017-12-31: $13.73M2018-12-31: $15.68M2019-12-31: $29.85M2020-12-31: $28.23M2021-12-31: $34.31M2022-12-31: $32.52M2023-03-31: $26.84M2023-06-30: $26.20M2023-12-31: $22.12M2024-03-31: $20.37M2024-06-30: $18.71M2024-09-30: $18.04M2024-12-31: $17.01M2025-12-31: $11.47M$11.47M
2010-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$11.47M-32.5%2026-03-30, Balance as of period end
2024-12-31$17.01Mn/a2026-03-30, Balance as of period end
2024-09-30$18.04Mn/a2025-03-31, Balance as of period end
2024-06-30$18.71Mn/a2025-03-31, Balance as of period end
2024-03-31$20.37Mn/a2025-03-31, Balance as of period end
2023-12-31$22.12Mn/a2025-03-31, Balance as of period end
2023-06-30$26.20Mn/a2025-03-31, Balance as of period end
2023-03-31$26.84Mn/a2025-03-31, Balance as of period end
2022-12-31$32.52M-5.2%2024-04-01, Balance as of period end
2021-12-31$34.31M+21.5%2023-03-27, Balance as of period end
2020-12-31$28.23M-5.4%2022-03-31, Balance as of period end
2019-12-31$29.85M+90.3%2021-04-01, Balance as of period end
2018-12-31$15.68Mn/c2021-01-19, Balance as of period end
2017-12-31$13.73M-61.0%2019-03-21, Balance as of period end
2016-12-31$35.25M-35.5%2018-03-23, Balance as of period end
2015-12-31$54.67M-42.9%2017-03-31, Balance as of period end
2014-12-31$95.78M+161.8%2016-03-30, Balance as of period end
2013-12-31$36.59M-14.6%2015-03-05, Balance as of period end
2012-12-31$42.82M-20.5%2014-03-06, Balance as of period end
2011-12-31$53.86M-1.9%2013-03-15, Balance as of period end
2010-12-31$54.88Mn/a2012-03-09, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Interpace Biosciences, Inc. (IDXG)2025-12-31$11.47M-32.5%
Utah Medical Products Inc (UTMD)2025-12-31$3.27M-35.9%
Retractable Technologies Inc (RVP)2025-12-31$68.26M-7.2%
Cytosorbents Corp (CTSO)2025-12-31$38.28M+5.6%
ClearPoint Neuro, Inc. (CLPT)2025-12-31$69.73M+405.3%
KORU Medical Systems, Inc. (KRMD)2025-12-31$11.15M+7.2%
SS Innovations International, Inc. (SSII)2025-12-31$36.01M+24.5%
SANUWAVE Health, Inc. (SNWV)2025-12-31$35.72Mn/a
Orchestra BioMed Holdings, Inc. (OBIO)2025-12-31$51.48M+19.1%

Compare IDXG, UTMD, RVP, CTSO side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗